| Name | Title | Contact Details |
|---|
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare diseases.
PAIGE is being built by a dedicated team of Machine Learning experts and pathologists from the leading cancer center in the US and experienced business leadership.
Founded in 2010, Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies.
Bioinformatics.org is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.